Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNY
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
SNY
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

SNY Price Prediction Next Week

Technical Analysis: SNY is currently showing a bullish momentum with RSI at 70.46, indicating an overbought condition. The stock closed at $52.48 on January 24, 2025, with a positive regular market change of +0.96%.

Fibonacci levels suggest key resistance at $52.20 (R1) and $53.34 (R2), while support levels are at $48.49 (S1) and $47.35 (S2). The stock is trading above both its 20-day SMA ($49.54) and 60-day SMA ($49.40), confirming an upward trend.

News Impact: Recent positive catalysts include:

  • EU approval for Sarclisa for newly diagnosed multiple myeloma patients
  • Global expansion with approvals in over 50 countries including US and EU

However, there's a negative factor:

  • FDA warning letter to Genzyme facility regarding quality control issues

Price Prediction for Next Week: Based on technical indicators and news sentiment:

  • Target Price: $53.30 (near R2 Fibonacci level)
  • Direction: Bullish with caution
  • Stop Loss: $51.20

Trading Recommendation: BUY with the following rationale:

  1. Strong momentum above key moving averages
  2. Positive news flow from EU approval
  3. Clear support levels for risk management

However, traders should be cautious of:

  1. Overbought RSI conditions
  2. Potential impact from FDA warning letter
  3. Market volatility around resistance levels

Technical Analysis: SNY is currently showing a bullish momentum with RSI at 70.46, indicating an overbought condition. The stock closed at $52.48 on January 24, 2025, with a positive regular market change of +0.96%.

Fibonacci levels suggest key resistance at $52.20 (R1) and $53.34 (R2), while support levels are at $48.49 (S1) and $47.35 (S2). The stock is trading above both its 20-day SMA ($49.54) and 60-day SMA ($49.40), confirming an upward trend.

News Impact: Recent positive catalysts include:

  • EU approval for Sarclisa for newly diagnosed multiple myeloma patients
  • Global expansion with approvals in over 50 countries including US and EU

However, there's a negative factor:

  • FDA warning letter to Genzyme facility regarding quality control issues

Price Prediction for Next Week: Based on technical indicators and news sentiment:

  • Target Price: $53.30 (near R2 Fibonacci level)
  • Direction: Bullish with caution
  • Stop Loss: $51.20

Trading Recommendation: BUY with the following rationale:

  1. Strong momentum above key moving averages
  2. Positive news flow from EU approval
  3. Clear support levels for risk management

However, traders should be cautious of:

  1. Overbought RSI conditions
  2. Potential impact from FDA warning letter
  3. Market volatility around resistance levels

SNY Similar Chart Price Prediction

The price of SNY is predicted to go up 3.31%, based on the high correlation periods with AMSF. The similarity of these two price pattern on the periods is 96.14%.

stocks logo

SNY

stocks logo

AMSF

Up: 3.31%Similarity: 96.14%

SNY Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

SNY Price Forecast($)

Potential Return(%)

2025

48.320

0.350

2026

65.000

34.990

2027

60.000

24.510

2028

72.000

49.530

2029

65.000

32.140

2030

75.000

52.470

What is SNY stock price prediction 2025 ?

SNY stock is currently priced at $48.32. Analysts predict a potential upside of over 34%, targeting $65 by the end of 2025. This projection is driven by expected growth in Sanofi's drug portfolio, including price increases on key vaccines and strong performance in its Dupixent collaboration.

What is SNY stock price prediction 2026 ?

The price prediction for SNY stock in 2026 is estimated to be around $65 per share. This projection is based on analysts' expectations of a 34% upside driven by strong growth in its vaccine and pharmaceutical segments, alongside consistent revenue increases. Additionally, Sanofi's strategic price adjustments and robust pipeline support this optimistic outlook.

What is SNY stock price prediction 2027 ?

Predicting the price of SNY stock in 2027 is challenging, but it could reach around $60. This estimate is based on anticipated growth in the pharmaceutical sector, driven by new drug approvals and an expanding global market. Additionally, strong financial performance and strategic acquisitions may further enhance its valuation.

What is SNY stock price prediction 2028 ?

SNY stock price prediction for 2028 is estimated at $72. This projection is based on anticipated growth in Sanofi's vaccine and drug portfolio, coupled with consistent revenue increases and strategic price adjustments. Additionally, the healthcare sector's resilience and Sanofi's strong market position support this optimistic outlook.

What is SNY stock price prediction 2029 ?

SNY stock is projected to reach $65 by 2029, driven by its robust late-stage pipeline and diversified business model. This estimate reflects a compound annual growth rate of approximately 5.6% from its current price of $49.73. Key growth drivers include expanding Dupixent sales and new product launches in oncology and rare diseases.

What is SNY stock price prediction 2030 ?

SNY stock's price prediction for 2030 is approximately $75-$85 per share. This projection is based on Sanofi's strong pipeline, including Dupixent's continued growth and potential new approvals, alongside steady revenue from vaccines and other drugs. However, risks such as patent expirations and competition in key markets could moderate growth.

SNY Revenue Forecast

SNY EPS Forecast

SNY FAQs

What is revenue forecast for next quarter？

The market consensus for 's revenue in the upcoming quarter is projected to be approximately $10.252B EUR.

What is eps forecast for next quarter？

The market consensus for 's eps in the upcoming quarter is projected to be approximately $0.861 EUR.

SNY VS S&P500

Sanofi is launching immunology drug Dupixent in several indications and the drug holds strong pricing power and major blockbuster potential across several indications.

Sanofi's strong entrenchment in rare-disease drugs should translate into steady pricing power as payers tend not to push back on pricing in these areas.

With a wide product offering in vaccines, consumer health and insulins, Sanofi is well positioned for the fast-growing emerging markets.

Ask Intellectia about SNY
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free